Shopping Cart
- Remove All
Your shopping cart is currently empty
ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2/3/4. It is used in the research on inflammatory diseases, cancer, and AIDS.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $39 | In Stock | |
| 2 mg | $54 | In Stock | |
| 5 mg | $97 | In Stock | |
| 10 mg | $153 | In Stock | |
| 25 mg | $315 | In Stock | |
| 50 mg | $455 | In Stock | |
| 100 mg | $555 | In Stock | |
| 200 mg | $798 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $97 | In Stock |
| Description | ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2/3/4. It is used in the research on inflammatory diseases, cancer, and AIDS. |
| Targets&IC50 | BRDT BD2:18 nM (IC50), BRD4 BD2:3 nM (Kd), BRD3 BD2:13 nM (IC50), BRD4 BD2:4 nM (IC50), BRD2 BD2:8 nM (IC50) |
| Synonyms | ABBV744 |
| Molecular Weight | 491.55 |
| Formula | C28H30FN3O4 |
| Cas No. | 2138861-99-9 |
| Smiles | CCNC(=O)c1cc2c(cn(C)c(=O)c2[nH]1)-c1cc(ccc1Oc1c(C)cc(F)cc1C)C(C)(C)O |
| Relative Density. | 1.262 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (91.55 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.07 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.